Compare ARK Innovation ETF (ARKK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs Twist Bioscience Corp — how do they compare? ARK Innovation ETF trades at $81.04, while Twist Bioscience Corp trades at $123.13 (market cap $7.82B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | TWST | |
|---|---|---|
52-Week High | $92.50 | $124.88 |
52-Week Low | $63.52 | $24.16 |
Market Cap | — | $7.82B |
Sector | — | Health |
Enterprise Value | — | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $79.43, up 4.89% today with strong technical momentum as moving averages signal bullish alignment. The ETF faces mixed sentiment with recent Seeking Alpha articles highlighting concentration risks in SpaceX and Tesla holdings while Cathie Wood continues aggressive AI stock purchases. Technical indicators show RSI at overbought levels near 82, suggesting potential near-term consolidation despite the bullish trend.
Outlook remains polarized between innovation optimism and valuation concerns. The fund's heavy exposure to speculative tech names offers growth potential but carries significant volatility risk. Recent underperformance versus broad market indices and high fee structure present headwinds, while continued institutional interest in disruptive technologies provides long-term catalysts.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
